Pharmacogenetics and immunosuppressive drugs in solid organ transplantation

被引：0
|
作者：
Teun van Gelder
Ron H. van Schaik
Dennis A. Hesselink
机构：
[1] Erasmus MC,Department of Hospital Pharmacy
[2] University Medical Center Rotterdam,Department of Clinical Chemistry
[3] Erasmus MC,Department of Internal Medicine
[4] University Medical Center Rotterdam,undefined
[5] Erasmus MC,undefined
[6] University Medical Center Rotterdam,undefined
来源：
Nature Reviews Nephrology | 2014年 / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The prediction made 15 years ago that pharmacogenetics would revolutionize pharmacotherapy has not materializedFor several immunosuppressive drugs, studies show significant associations between polymorphisms in genes encoding metabolizing enzymes and pharmacokinetic dataStudies showing a clinical benefit if immunosuppressive drug dose is based on pharmacogenetic data are lackingEfficient therapeutic drug monitoring can rapidly correct for deviations in drug exposureTreatment algorithms that include polymorphisms in genes encoding pharmacodynamic parameters, drug transporter proteins, and predictors of toxicity will provide additional benefit
引用
收藏
页码：725 / 731
页数：6
相关论文
共 50 条
  • [31] The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation
    Dennis A. Hesselink
    Rachida Bouamar
    Laure Elens
    Ron H. N. van Schaik
    Teun van Gelder
    Clinical Pharmacokinetics, 2014, 53 : 123 - 139
  • [32] Pharmacogenetics in solid organ transplantation: a transition from kinetics to dynamics
    Kuypers, Dirk R. J.
    PHARMACOGENOMICS, 2012, 13 (15) : 1679 - 1679
  • [33] Pharmacogenetics in solid organ transplantation: Present knowledge and future perspectives
    Anglicheau, D
    Legendre, C
    Thervet, E
    TRANSPLANTATION, 2004, 78 (03) : 311 - 315
  • [34] Progress in Immunosuppressive Agents for Solid-Organ Transplantation
    Zhang, Wynne Qing
    Vierling, John M.
    TEXAS HEART INSTITUTE JOURNAL, 2019, 46 (01): : 69 - 70
  • [35] Solid organ transplantation - Immunologic theory and immunosuppressive strategy
    Kahan, BD
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 1996, 16 (02) : 221 - &
  • [36] Update of current immunosuppressive drugs used in clinical organ transplantation
    Braun, F
    Lorf, T
    Ringe, B
    TRANSPLANT INTERNATIONAL, 1998, 11 (02) : 77 - 81
  • [37] Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?
    MacPhee, IA
    Fredericks, S
    Holt, DW
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (15) : 2593 - 2605
  • [38] Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation
    Liang, Fu N. G.
    Holt, David W.
    MacPhee, Iain A. M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (13) : 2045 - 2058
  • [39] Current status of immunosuppressive agents for solid organ transplantation in children
    Coelho, Tracy
    Tredger, Michael
    Dhawan, Anil
    PEDIATRIC TRANSPLANTATION, 2012, 16 (02) : 106 - 122
  • [40] Metabolic consequences of modern immunosuppressive agents in solid organ transplantation
    Bamgbola, Oluwatoyin
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2016, 7 (03) : 110 - 127
12345